TP53 and cancer: The MSI–CIN– cancers presented at an earlier stage (102/180 versus 244/557 stage II, respectively; p = 0.003, q = 0.01) had lower frequencies of TP53 mutation and 17p LOH, and showed a borderline association with KRAS mutation (see Supplementary material, Tables S2, S3).